Literature DB >> 24805788

Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for Graves' disease.

Min Liu1, Danqing Jing, Jingsheng Hu, Shinan Yin.   

Abstract

BACKGROUND: Graves' disease (GD) is the most common cause of hyperthyroidism in iodine-sufficient areas. Radioactive iodine I treatment (RIT), as the 1st therapeutic option, is widely accepted by doctors and patients. The aim of this study was to investigate factors influencing the success rate of calculated RIT in GD.
METHODS: Thyroid function outcome (hyperthyroidism or euthyroidism/hypothyroidism) was verified retrospectively at least 1 year after RIT and was compared with presenting clinical characteristics and pre-RIT parameters in 167 patients with GD treated with I-iodide in the authors' institute.
RESULTS: After RIT, 83 patients (49.7%) became euthyroid, 64 patients (38.3%) became hypothyroid and 20 (12.0%) remained hyperthyroid. Multiple logistic regression analyses demonstrated that there was no statistically significant association between RIT outcomes and sex, age, history of GD, previous antithyroid drug treatment, thyroid hormone levels, thyroid gland mass or radioactive iodine I dosage. The only variables associated with the success rate were the course of disease over 6 months (odds ratio, 3.70; confidence interval, 1.75-7.17; P = 0.014) and 2-hour radioactive iodine uptake (RAIU) >58.5% (odds ratio, 4.08; confidence interval, 2.03-7.83; P = 0.005).
CONCLUSIONS: Our study has shown that a calculated approach for the treatment of GD was effective, but high failure rates were observed in patients presenting higher 2-hour RAIU, particularly those with 2-hour RAIU of more than 58.5%.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24805788     DOI: 10.1097/MAJ.0000000000000288

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  9 in total

1.  Clinical efficacy of fixed-dose radioactive iodine for the treatment of hyperthyroidism at a single centre: our experience.

Authors:  Dilip Nair; Robert Maweni; Christoforos Constantinou; Shivanthi Kandiah; Sidhartha Nagala; Theingi Aung
Journal:  Ir J Med Sci       Date:  2021-09-18       Impact factor: 2.089

2.  Predictive factors for the outcomes of Graves' disease patients with radioactive iodine (131I) treatment.

Authors:  Yu-Zhuo Xing; Kun Zhang; Gang Jin
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

3.  Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy.

Authors:  Feng Yu; Ruiguo Zhang; Guizhi Zhang; Zhaowei Meng; Xiaohua Liu; Yajing He; Jian Tan; Renfei Wang
Journal:  Med Sci Monit       Date:  2021-01-26

4.  A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease.

Authors:  Jan Taprogge; Paul M D Gape; Lily Carnegie-Peake; Iain Murray; Jonathan I Gear; Francesca Leek; Steve L Hyer; Glenn D Flux
Journal:  Thyroid       Date:  2021-12       Impact factor: 6.568

5.  Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves' Disease.

Authors:  Min Joo Kim; Sun Wook Cho; Ye An Kim; Hoon Sung Choi; Young Joo Park; Do Joon Park; Bo Youn Cho
Journal:  Endocrinol Metab (Seoul)       Date:  2022-06-16

6.  Response to Radioiodine Therapy for Thyrotoxicosis: Disparate Outcomes for an Indigenous Population.

Authors:  Jade A U Tamatea; John V Conaglen; Marianne S Elston
Journal:  Int J Endocrinol       Date:  2016-06-29       Impact factor: 3.257

7.  Predictors of euthyreosis in hyperthyroid patients treated with radioiodine 131I-: a retrospective study.

Authors:  Albert Stachura; Tomasz Gryn; Bernadetta Kałuża; Tadeusz Budlewski; Edward Franek
Journal:  BMC Endocr Disord       Date:  2020-06-01       Impact factor: 2.763

8.  Comparison Between the Treatment Modalities for Graves' Disease at King Abdulaziz Medical City, Jeddah.

Authors:  Hawazen A Zarif; Sultan S Alam; Abdulrahman Baashar; Abdulaziz Alsharif; Mashael Alhilabi
Journal:  Cureus       Date:  2020-01-21

9.  Age moderates the associations between TRAbs, free T3 and outcomes of Graves' disease patients with radioactive iodine treatment.

Authors:  Lusi Lu; Chenlu Gao; Nan Zhang
Journal:  Clin Endocrinol (Oxf)       Date:  2020-08-13       Impact factor: 3.478

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.